Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

Juvekar Ashish; Ruggeri Bruce; Condon Sindy; Borkowski Andrew; Huber Reid; Smith Paul

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

【24h】

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

机译：ruxolitinib，jak1 / jak2选择性抑制剂在皮质类固醇未经治疗和难治性MHC - 错配的急性GVHD小鼠模型中具有高度效力

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2018年第novaelatreatmentappr期| 共2页
作者
Juvekar Ashish; Ruggeri Bruce; Condon Sindy; Borkowski Andrew; Huber Reid; Smith Paul;
展开▼
作者单位

Incyte Corp Chadds Ford PA USA;

Incyte Corp Wilmington DE USA;

Incyte Corp Wilmington DE USA;

Biomodels LLC Watertown MA USA;

Incyte Res Inst Wilmington DE USA;

Incyte Corp Wilmington DE USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD [J] . Juvekar Ashish, Ruggeri Bruce, Condon Sindy, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：ruxolitinib，jak1 / jak2选择性抑制剂在皮质类固醇未经治疗和难治性MHC - 错配的急性GVHD小鼠模型中具有高度效力
2. Ruxolitinib, A JAK1/JAK2 Inhibitor, Significantly Prolongs Survival in Both Primary Mediastinal B-Cell Lymphoma & Hodgkin Lymphoma Xenograft NSG Mouse Model: A Potential Targeted Adjuvant Therapy [J] . Lee S., Yin C., Shah T., Pediatric blood & cancer . 2016 ,第Suppla3期

机译：Ruxolitinib，JAK1 / JAK2抑制剂，在原发性纵隔B细胞淋巴瘤和霍奇金淋巴瘤异种移植NSG小鼠模型中均显着延长生存期：潜在的靶向辅助治疗
3. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma [J] . Eric Van Den Neste, Marc André, Thomas Gastinne, Haematologica . 2018 ,第5期

机译：口服JAK1 / JAK2抑制剂ruxolitinib在晚期复发/难治性霍奇金淋巴瘤中的II期研究
4. Green tea inhibits methylation of the RXRalpha gene and selectively targets initial stages of intestinal carcinogenesis in the AOM-MIN mouse model. [D] . Issa, Ala Y. 2005

机译：绿茶抑制RXRalpha基因的甲基化，并选择性地靶向AOM-MIN小鼠模型中肠癌发生的初始阶段。
5. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma [O] . Eric Van Den Neste, Marc André, Thomas Gastinne, 2018

机译：口服JAK1 / JAK2抑制剂ruxolitinib在晚期复发/难治性霍奇金淋巴瘤中的II期研究
6. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma [O] . Eric Van Den Neste, Marc André, Thomas Gastinne, 2018

机译：先进复发/难治霍奇金淋巴瘤中口腔JAK1 / JAK2抑制剂Ruxolitinib的II期研究

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

著录项

相似文献

相关主题

期刊订阅